Ozari Health Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.4/10
Best for: semaglutide at $86/month, 54% under the register median
What Ozari Health does best is charge less than most of the register.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Ozari Health prices physician-prescribed compounded semaglutide from $86/month and tirzepatide from around $149/month, shipping included. Board-certified physicians review the online intake and prescribe if appropriate, with medications compounded in 503A and 503B facilities. It is LegitScript certified and operated by Ozari LLC. The site publishes state-by-state pages but does not clearly list every state it serves, and it does not name its specific pharmacies.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Ozari Health
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Ozari Health at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide from $86
- Starting price
- $86/mo (From $86/mo; starts at $99, ranges to ~$348 by dose/plan; shipping included)
- What's included
- Consult · Shipping · Medication
- FDA status
- No FDA warning letter on record
How Ozari Health scores
Six columns, each one computed from something Ozari Health has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
10.0/10$86/month is 54% below the register median of $189 for compounded semaglutide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Ozari Health
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Ozari Health involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Ozari Health publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Ozari Health does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $86, tirzepatide $149. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether Ozari Health serves your state cannot be confirmed from its site.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Ozari Health support, as documented
- Phone
- (302) 316-5231
- care@ozarihealth.com
GLP-1 medications Ozari Health offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
From $86/mo; starts at $99, ranges to ~$348 by dose/plan; shipping included
From ~$149/mo; higher tiers by dose/plan (approximate)
Check the price yourself before you pay
Every figure here was read off Ozari Health's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $86 a month, 54% below the $189 median for the same drug and form across this register
- Tirzepatide at $149 a month, 44% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Ozari Health charges
Ozari Health charges $86/month. That sits at the affordable end of what we track.
- semaglutide — $86/month
- tirzepatide — $149/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so Ozari Health is genuinely under the middle rather than merely advertising that it is.
PreventiveMD dispenses semaglutide and tirzepatide from $83/month, which makes it the honest comparison to run before committing here.
What Ozari Health dispenses
Ozari Health prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data.
What we could verify
On the record: it dispenses through an accredited compounding pharmacy. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
Our read
Ozari Health competes on price and does it without an obvious sacrifice elsewhere: $86/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
What Ozari Health does best is charge less than most of the register.
Before you pay Ozari Health
Starting at $86/month. Check today's price, then book the free consultation.
Where Ozari Health is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Ozari Health review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Ozari Health's current pricing
Plans start at $86/month. The free consultation is where you learn whether you qualify, and what it costs today.